Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
50
LGND Quote, Financials, Valuation and Earnings
Last price:
$113.85
Seasonality move
:
9.17%
Day range:
$111.00 - $115.47
52-week range:
$67.53 - $129.90
Dividend yield:
0%
P/E ratio:
45.65x
P/S ratio:
13.58x
P/B ratio:
2.57x
Volume:
528.7K
Avg. volume:
139K
1-year change:
65.27%
Market cap:
$2.2B
Revenue:
$131.3M
EPS (TTM):
$2.51
Analysts' Opinion
-
Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Ligand Pharmaceuticals has an estimated upside of 25.68% from its current price of $114.58.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $114.58.
Fair Value
-
According to the consensus of 0 analysts, Ligand Pharmaceuticals has 25.68% upside to fair value with a price target of -- per share.
LGND vs. S&P 500
-
Over the past 5 trading days, Ligand Pharmaceuticals has underperformed the S&P 500 by -0.01% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ligand Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ligand Pharmaceuticals has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Ligand Pharmaceuticals reported revenues of $51.8M.
Earnings Growth
-
Ligand Pharmaceuticals has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Ligand Pharmaceuticals reported earnings per share of -$0.39.
Enterprise value:
1.9B
EV / Invested capital:
2.31x
Price / LTM sales:
13.58x
EV / EBIT:
31.84x
EV / Revenue:
12.76x
PEG ratio (5yr expected):
0.23x
EV / Free cash flow:
279.19x
Price / Operating cash flow:
296.99x
Enterprise value / EBITDA:
20.25x
Gross Profit (TTM):
$142.5M
Return On Assets:
5.27%
Net Income Margin (TTM):
29.68%
Return On Equity:
5.97%
Return On Invested Capital:
5.97%
Operating Margin:
21.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $182.7M | $153.6M | $152.4M | $32.9M | $51.8M | |
| Gross Profit | $139.6M | $123.1M | $142.5M | $29.4M | $49.4M | |
| Operating Income | $60.8M | -$6.9M | $18M | $957K | $11M | |
| EBITDA | $89M | $110.2M | $96M | -$3.5M | $3.4M | |
| Diluted EPS | -$1.24 | $0.83 | $2.51 | -$0.59 | -$0.39 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $857.7M | $432.1M | $220.4M | $254M | $309.4M | |
| Total Assets | $1.2B | $1.3B | $1.1B | $769.2M | $954.9M | |
| Current Liabilities | $42.3M | $36.3M | $135.2M | $15.7M | $24.8M | |
| Total Liabilities | $549.6M | $461.6M | $234.3M | $101.3M | $113.7M | |
| Total Equity | $697.8M | $812.1M | $816.3M | $667.9M | $841.2M | |
| Total Debt | $455M | $316.9M | $76.6M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $112M | $95M | $76.6M | $7.6M | $36.5M | |
| Cash From Investing | $135.2M | -$8.7M | -$115.3M | -$19.5M | -$46.5M | |
| Cash From Financing | -$266.5M | -$70.6M | $82.1M | $3.3M | $55.1M | |
| Free Cash Flow | $93.1M | $90.7M | $7M | $7.2M | $22.3M | |
LGND
Sector
Market Cap
$2.2B
$43.9M
Price % of 52-Week High
88.21%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
65.27%
-29.11%
Beta (5-Year)
1.038
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$117.05
200-day SMA
Buy
Level
$95.37
Bollinger Bands (100)
Buy
Level
100.49 - 116.81
Chaikin Money Flow
Buy
Level
2.1M
20-day SMA
Sell
Level
$119.57
Relative Strength Index (RSI14)
Sell
Level
46.42
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-78.7663
50-day SMA
Sell
Level
$114.96
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
20.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.3844)
Buy
CA Score
(Annual)
Level (1.5255)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-5.0983)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Stock Forecast FAQ
In the current month, LGND has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LGND average analyst price target in the past 3 months is --.
-
Where Will Ligand Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ligand Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Ligand Pharmaceuticals?
Analysts are divided on their view about Ligand Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ligand Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Ligand Pharmaceuticals's Price Target?
The price target for Ligand Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LGND A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ligand Pharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LGND?
You can purchase shares of Ligand Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ligand Pharmaceuticals shares.
-
What Is The Ligand Pharmaceuticals Share Price Today?
Ligand Pharmaceuticals was last trading at $113.85 per share. This represents the most recent stock quote for Ligand Pharmaceuticals. Yesterday, Ligand Pharmaceuticals closed at $114.58 per share.
-
How To Buy Ligand Pharmaceuticals Stock Online?
In order to purchase Ligand Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
